Introduction {#s1}
============

Uric acid, a key end-product of purine metabolism, has a controversial role in human physiology acting potentially both as a pro-oxidant and selective antioxidant depending on its environmental milieu. It functions as an antioxidant primarily in extracellular compartment and as a pro-oxidant within the cells. While its role as a pro-oxidant in cardio-metabolic and cardiovascular diseases is well established, it has been observed that subjects with elevated serum uric acid (SUA) have lower prevalence of neurodegenerative diseases like multiple sclerosis, Parkinson\'s disease and Alzheimer\'s disease [@pone.0076336-Church1], [@pone.0076336-deLau1], [@pone.0076336-Kim1], [@pone.0076336-Toncev1]. Such a neuroprotective effect of SUA could be attributed to its antioxidant properties. Uric acid is capable of scavenging superoxide and hydroxyl radicals [@pone.0076336-Ames1], [@pone.0076336-Davies1] and accounts for over 60% of total antioxidant capacity in the human blood [@pone.0076336-Ames1].

Though studies examining the role of SUA in affective disorders like major depressive disorder (MDD) and anxiety disorders are scant, the available evidence suggests a protective role of SUA in both depression [@pone.0076336-Bove1], [@pone.0076336-Chaudhari1], [@pone.0076336-Wen1] and anxiety [@pone.0076336-Francis1]. The exact pathophysiologic mechanism linking SUA to these disease states is still unclear. Oxidative stress-related pathways have been implicated in depression and anxiety based mostly on experimental evidence [@pone.0076336-Bouayed1], [@pone.0076336-Hovatta1], [@pone.0076336-Hovatta2], [@pone.0076336-Salim1] and also several studies in humans [@pone.0076336-Matsushita1], [@pone.0076336-Yanik1]. Hence, one possible mechanism by which SUA exerts its protective effect could be via a decrease in oxidative stress.

The few studies that have looked at the relation between SUA and MDD and anxiety disorders [@pone.0076336-Bove1], [@pone.0076336-Chaudhari1], [@pone.0076336-Wen1], [@pone.0076336-Francis1] have methodological limitations which include small sample sizes and/or samples not representative of the general population. Hence, the current analysis explored the relationship between SUA and the lifetime and current occurrence of the commonest psychiatric disorders including the subtypes of MDD and specific anxiety disorders in individuals from a large population-based study. In addition, we examined the associations between a key variant of the *SLC2A9* gene which has been shown to have a strong association with SUA in genome-wide association studies [@pone.0076336-Brandstatter1], [@pone.0076336-Vitart1] and anxiety disorders.

Methods {#s2}
=======

Study population {#s2a}
----------------

Current analyses are performed within the PsyCoLaus study which is the psychiatric arm of the CoLaus study, a population-based study that assessed cardiovascular disease (CVD) risk factors and genetic variants associated with these conditions in Lausanne, Switzerland. Details of the CoLaus have been previously described [@pone.0076336-Firmann1]. Briefly, the random sampling procedure was based on a complete list of the Lausanne inhabitants aged 35--75 years in 2003, provided by the population register of the city. Sixty-seven percent of the CoLaus participants in the age range between 35 and 66 years (n = 5,535) accepted the psychiatric evaluation between 2004 and 2008, which resulted in a sample of 3,716 individuals who underwent both the medical and psychiatric exam [@pone.0076336-Preisig1]. Ninety-two percent of them were Caucasians. The gender distribution of the PsyCoLaus sample (47% males) did not differ significantly from that of the general population in the same age range. Although the youngest 5-year band of the cohort was underrepresented and the oldest 5-year band overrepresented, participants of PsyCoLaus (mean age 50.9±8.8 years) and individuals who refused to participate revealed comparable scores on the General Health Questionnaire (GHQ-12 [@pone.0076336-Goldberg1]; French translation [@pone.0076336-Bettschart1]), a self-rating instrument completed at the somatic exam. Both CoLaus and PsyCoLaus were approved by the Ethics Committee of the University of Lausanne. A written informed consent was obtained only from individuals without any apparent disability or handicap that might suggest the participant\'s incapability to participate in the study.

Study procedure and measurements {#s2b}
--------------------------------

### Evaluations within the CoLaus study {#s2b1}

Participants of the CoLaus study were seen in the outpatient clinic of the Centre Hospitalier Universitaire Vaudois (CHUV) in the morning after an overnight fast. They were asked to continue taking their medications as usual. The examination included a detailed health questionnaire, physical examination with anthropometric measures by trained and certified field workers and laboratory testing. Information on drugs that influence uric acid was assessed by recording all the prescribed drugs taken by the participants and was considered as present if participants were using any drugs including acetylsalicylic acid, diuretics, angiotensin converting enzymes inhibitors, angiotensin receptor blockers and other drugs known to induce hyperuricemia and hypouricemics (e.g., allopurinol, probenecid etc.). Blood pressure was measured in triplicate on the left arm and blood pressure values are the mean between the last two readings. Most clinical assays were performed by the CHUV Clinical Laboratory on fresh fasting blood samples. Glucose was measured by glucose dehydrogenase (2.1% - 1.0% maximum inter and intra-batch coefficients of variation); serum and urinary creatinine by Jaffe kinetic compensated method (2.9% - 0.7%) and uric acid by uricase-PAP (1.0% - 0.5%). Glomerular filtration rate (GFR) was estimated using the abbreviated Modification of the Diet in Renal Disease (MDRD) formula: 186×(serum creatinine \[µmol/L\]/88.4) (−1.154)×age (−0.203)×F, where F = 1 for men and F = 0.742 for women [@pone.0076336-Levey1].

Hypertension was defined as mean systolic blood pressure of ≥140 mmHg or mean diastolic blood pressure of ≥90 mmHg and/or presence of anti-hypertensive medication. A diagnosis of diabetes was made if fasting plasma glucose was greater than or equal to 7.0 mmol/l or presence of oral hypoglycaemic or insulin treatment.

### Evaluations within PsyColaus study {#s2b2}

Diagnostic information was collected using the semi-structured Diagnostic Interview for Genetic Studies (DIGS) [@pone.0076336-Nurnberger1]. The DIGS was developed by the NIMH Molecular Genetics Initiative to obtain a more precise assessment of phenotypes through wide spectrum of DSM-IV Axis I criteria. The French translation of the DIGS [@pone.0076336-Leboyer1] used in this study was jointly developed by the Department of Psychiatry of Lausanne and the INSERM in Paris and had several modifications. Additional questions were added to the depression section in order to elicit criteria for atypical depression features (leaden paralysis, long-standing patterns of interpersonal rejection sensitivity, mood reactivity). Similarly, a section on generalized anxiety disorder (GAD) was added using questions from the Schedule for Affective Disorders and Schizophrenia-Lifetime (SADS-LA) version and the brief phobia chapter of the DIGS was replaced by the corresponding more extensive chapters from the SADS-LA [@pone.0076336-Endicott1]. The French version of the DIGS had excellent inter-rater reliability for kappa and Yule\'s Y coefficient for major mood disorders [@pone.0076336-Preisig2] but 6-week test-retest reliability was slightly lower [@pone.0076336-Preisig2]. Similarly, the French translation of the SADS-LA revealed satisfactory test-retest reliability for anxiety disorders [@pone.0076336-Leboyer2]. In our own reliability study we found excellent or perfect inter-rater reliability for all specific anxiety disorders, whereas the 6-week test-retest reliability estimates were in the fair or good range [@pone.0076336-RougemontBuecking1]. Lifetime and current (at the time of interview) diagnoses of depression and anxiety disorders were assigned according to DSM-IV criteria. The specifier for atypical depression features according to DSM-IV requires mood reactivity (the capacity to be cheered up when presented with positive events) and at least two of the following four symptoms: 1) increased appetite or significant weight gain, 2) hypersomnia, 3) leaden paralysis (i.e., heavy, leaden feelings in arms or legs), and 4) a long-standing pattern of interpersonal rejection sensitivity. According to Angst et al. [@pone.0076336-Angst1], we used these criteria in a non-hierarchical way (depressive episode meeting at least 3 out of the 5 DSM-IV criteria of the atypical depression features specifier). For melancholic depression features, we applied the DSM-IV specifier which requires either a loss of energy or a lack of mood reactivity and 3 out of the following 5 symptoms: 1) depression regularly worse in the morning, 2) early morning awakening, 3) psychomotor retardation or agitation, 4) decreased appetite (we did not consider weight loss as a criterion) and 5) excessive guilt. We could not take into account the 6^th^ DSM-IV criterion "distinct quality of depressed mood" because it was not assessed in the DIGS. Following Angst et al. [@pone.0076336-Angst1], MDD was subtyped according to the history of atypical or melancholic features into four subtypes 1) MDD with atypical features only, 2) MDD with melancholic features only, 3) combined MDD with atypical and melancholic features simultaneously or during distinct episodes and 4) unspecified MDD with neither atypical, nor melancholic features. All interviews were conducted by psychologists and psychiatrists trained over a two-month period. Their training included rating tapes and supervised co-ratings. Each interview and diagnostic assignment was reviewed by an experienced senior psychologist.

Socio-economic status was assessed using the Hollingshead scale [@pone.0076336-Hollingshead1]. Smoking was defined as current or past history of regular daily consumption of at least 10 cigarettes. Alcohol consumption was defined as glasses per typical week of consumption.

### Genotyping {#s2b3}

Nuclear DNA was extracted from whole blood for whole genome scan analysis. Genotyping was performed using Affymetrix 500K SNP chip, as recommended by the manufacturer (Affymetrix, Inc., Santa Clara, California, USA) on all participants of the CoLaus study. Persons with less than 95% genotyping efficiency overall (or \<90% efficiency on either array; n = 399) and persons with possible gender inconsistencies (n = 5) were removed. Monomorphic single nucleotide polymorphisms (SNPs), SNPs with less than 70% genotyping efficiency, SNPs with minor allele frequency less than 1%, and/or not in the Hardy-Weinberg proportions were excluded. The SNP *rs6855911* in the *SLC2A9* gene was considered for the present analysis.

Statistical analysis {#s2c}
--------------------

All tests were performed using Stata 11 (StataCorp, College Station, TX, USA). Continuous variables were summarized as mean (standard deviation) or median (interquartile range) while categorical variables as number of subjects and percentages. We used t test (or Wilcoxon rank sum test) and χ2 test to compare the distribution of covariates according to sex. We described the distribution of MDD and anxiety disorders across sex-specific SUA quintiles and across genotypes of *rs6855911* within the *SLC2A9* gene and assessed for trends across these groups by using a non-parametric test which is an extension of the Wilcoxon rank-sum test [@pone.0076336-Cuzick1]. These quintiles were generated separately in men and women, which leads to an equal proportion of men and women across quintiles.

We constructed multiple logistic regression models to examine the associations of SUA as independent variable of interest with MDD, MDD subtypes or specific anxiety disorders as dependent variable, one at a time. The predictor variable SUA was modeled as a continuous variable. Co-variates that were known to potentially influence the associations such as age, sex, socio-economic status, smoking, alcohol consumption, diabetes, hypertension, GFR and drugs that influence SUA were included in the models. Because depression and anxiety tend to co-exists [@pone.0076336-Hettema1], [@pone.0076336-Kessler1], we additionally adjusted for any anxiety disorder (in the association between SUA and depression) and MDD (in the association between SUA and anxiety). Furthermore, we included a quadratic term for SUA (i.e. SUA squared) in the models to account for non-linear relationship and used a likelihood ratio test (LRT) to compare model assuming a linear trend for SUA with another estimating quadratic fit; we maintained a quadratic model if the quadratic term was significant and P-value from the LRT was \<0.05. Stratified analyses by sex were also conducted. We presented the quadratic relationship between SUA and social phobia graphically by plotting the fitted predicted probabilities after adjusting for the co-variates across SUA levels and by presenting the distribution of lifetime social phobia in men and women across genotypes of *SLC2A9 rs6855911* variant.

To test the potential modification of this association by sex, we included a multiplicative interaction parameter between sex and SUA into the logistic models. For models which included a quadratic term for SUA, interaction by sex was determined by LRT comparing a model with the multiplicative interaction parameters (SUA\*sex and SUA squared\*sex) to one without. We also performed logistic regression analyses where we further modeled *SLC2A9 rs6855911* as a score (where 0 = homozygote for non-risk allele, 1 = heterozygote and 2 = homozygote for risk allele) with anxiety disorders. The results from the genetic analyses serve to validate findings from logistic models using phenotypic SUA. We also tested the sex-by-genotype interaction for its effect on anxiety disorders in models including both men and women.

Results {#s3}
=======

[**Table 1**](#pone-0076336-t001){ref-type="table"} characterizes the demographic and clinical characteristics of the participants according to sex. SUA was significantly higher in men (357±74 µmol/L) than in women (263±64 µmol/L). Men had significantly higher prevalence of reported alcohol consumption and smoking compared to women. The overall prevalence estimates of diabetes and hypertension in the study population were 5% and 28% respectively, with significantly higher prevalence in men. The frequency of mental disorders in the overall population was high, with prevalence of lifetime and current MDD being 44% and 18% respectively. The corresponding prevalence estimates for any anxiety disorders were 18% and 10% respectively. Women consistently showed significantly higher lifetime as well as current prevalence of all subtypes of MDD and specific anxiety disorders (p\<0.001 in almost all cases).

10.1371/journal.pone.0076336.t001

###### Characteristics of the PsyCoLaus participants.
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                                                                    Overall (N = 3716)   Men (N = 1748)   Women (N = 1968)                                            
  ---------------------------------------------------------------- -------------------- ---------------- ------------------ ---------------- -------- --------------- -----------
  **Age (years)** [\*](#nt102){ref-type="table-fn"}                        3716            50.9(8.8)            1748           50.5(8.8)       1968      51.3(8.8)       0.006
  **Alcohol consumption** [§](#nt101){ref-type="table-fn"}                 3716          3.0(0.0--8.0)          1748         6.0(2.0--14.0)    1968    2.0(0.0--5.0)    \<0.001
  **Daily smoking (\>10 cigarettes)**                                      1655               44.5              869               49.7         786         39.9         \<0.001
  **Diabetes**                                                             194                5.2               139               8.0           55          2.8         \<0.001
  **Hypertension**                                                         1046               28.2              588               33.6         458         23.3         \<0.001
  **Drugs influencing uric acid levels**                                   471                13.8              247               15.3         224         12.4          0.014
  **Serum uric acid (µmol/L)** [\*](#nt102){ref-type="table-fn"}           3710           307.1(83.5)           1744          357.2(73.7)      1966     262.6(64.3)     \<0.001
  **GFR (ml/min/1.73 m^2^)** [\*](#nt102){ref-type="table-fn"}             3709            84.4(15.8)           1743           87.2(0.4)       1966      81.9(0.3)      \<0.001
  ***Lifetime pyschiatric disorders***                                                                                                                                
  *MDD*                                                                   *1625*             *43.7*            *565*             *32.3*       *1060*      *53.9*       *\<0.001*
  Combined MDD                                                             218                5.9                61               3.5          157          8.0         \<0.001
  Atypical MDD                                                             236                6.4                70               4.0          166          8.4         \<0.001
  Melancholic MDD                                                          449                12.1              151               8.6          298         15.1         \<0.001
  Unspecified MDD                                                          722                19.4              283               16.2         439         22.3         \<0.001
  *Any anxiety disorder*                                                  *660*              *17.8*            *225*             *12.9*       *435*       *22.1*       *\<0.001*
  GAD                                                                       85                2.3                29               1.7           56          2.9          0.043
  Panic disorder                                                           118                3.2                30               1.7           88          4.5         \<0.001
  Agoraphobia                                                              139                3.7                32               1.8          107          5.4         \<0.001
  Social phobia                                                            444                12.0              162               9.3          282         14.3         \<0.001
  ***Current psychiatric disorders***                                                                                                                                 
  *MDD*                                                                   *660*              *17.8*            *236*             *13.5*       *424*       *21.5*       *\<0.001*
  Combined MDD                                                             106                2.9                30               1.7           76          3.9         \<0.001
  Atypical MDD                                                              98                2.6                31               1.8           67          3.4          0.002
  Melancholic MDD                                                          198                5.3                66               3.8          132          6.7         \<0.001
  Unspecified MDD                                                          258                6.9               109               6.2          149          7.6          0.110
  *Any anxiety disorder*                                                  *370*              *10.0*            *118*             *6.8*        *252*       *12.8*       *\<0.001*
  GAD                                                                       0                 0.0                0                0.0           0           0.0           NA
  Panic disorder                                                            1                 0.0                0                0.0           1           0.1           NA
  Agoraphobia                                                               88                2.4                21               1.2           67          3.4         \<0.001
  Social phobia                                                            294                7.9                98               5.6          196         10.0         \<0.001

median (interquartile range);

mean (standard deviation).

GFR = glomerular filtration rate; MDD = major depressive disorder; and GAD = generalized anxiety disorder.

[**Table 2**](#pone-0076336-t002){ref-type="table"} describes the distribution of the lifetime and current prevalences of MDD and anxiety disorders across sex-specific quintiles of SUA in the overall sample. A significant negative linear trend was observed for anxiety disorder, in general, and for social phobia, in particular, suggesting lower prevalence of lifetime and current social phobia at higher levels of SUA. However, this decreasing trend in prevalence of social phobia was only up to a certain level of SUA after which an increase in prevalence was detected. Testing for comparison of fit of linear versus quadratic model indicated that a quadratic curve might explain the relationship better than a linear trend. In stratified analysis by sex (**[Tables S1](#pone.0076336.s003){ref-type="supplementary-material"} and [S2](#pone.0076336.s004){ref-type="supplementary-material"}**), a hockey-stick shaped relationship (i.e. lowest prevalence in the fourth quartile) between SUA and lifetime and current social phobia was observed in women, although the quadratic test for trend was not statistically significant (P-value for quadratic trend = 0.153 and 0.087 respectively). A hockey-stick shaped relationship also tended to be present in men (P-value for quadratic trend = 0.095 and 0.210 respectively), although less clear than in women, possibly owing to the small number of cases of social phobia in each SUA quintile. **[Figure S1](#pone.0076336.s001){ref-type="supplementary-material"}** depicts the quadratic trend between SUA and social phobia based on adjusted predicted probabilities of social phobia across SUA levels from a multiple logistic regression model.

10.1371/journal.pone.0076336.t002

###### Distribution of psychiatric disorders across sex-specific quintiles of SUA.

![](pone.0076336.t002){#pone-0076336-t002-2}

  SUA (mean, µmol/L)                      Q1 224        Q2 273        Q3 306        Q4 343        Q5 422                          P-trend
  ------------------------------------ ------------- ------------- ------------- ------------- ------------- --------------------------------------------------
  **Lifetime pyschiatric disorders**                                                                         
  *MDD*                                 *348(47.2)*   *323(45.4)*   *296(40.8)*   *259(40.1)*   *251(42.5)*   *0.012(−2.51)* [\*](#nt105){ref-type="table-fn"}
  Combined MDD                            45(6.1)       44(6.2)       46(6.3)       33(5.1)       35(5.9)                       0.624(−0.49)
  Atypical MDD                            46(6.2)       45(6.3)       39(5.4)       44(6.8)       40(6.8)                       0.623(0.49)
  Melancholic MDD                        104(14.1)     94(13.2)      76(10.5)       64(9.9)      70(11.9)                       0.038(−2.07)
  Unspecified MDD                        153(20.7)     140(19.7)     135(18.6)     118(18.3)     106(18.0)                      0.144(−1.46)
  *Any anxiety disorder*                *162(22.0)*   *126(17.9)*   *130(18.0)*   *102(15.9)*   *103(17.6)*   *0.015(−2.43)* [\*](#nt105){ref-type="table-fn"}
  GAD                                     15(2.0)       16(2.3)       14(1.9)       16(2.5)       17(2.9)                       0.316(1.00)
  Panic disorder                          24(3.3)       17(2.4)       30(4.2)       26(4.0)       14(2.4)                       0.965(0.04)
  Agoraphobia                             26(3.5)       26(3.7)       34(4.7)       29(4.5)       20(3.4)                       0.735(0.34)
  Social phobia                          126(17.1)     84(11.9)      84(11.7)       55(8.6)      70(11.9)     \<0.001(−3.62)[\*](#nt105){ref-type="table-fn"}
  **Current psychiatric disorders**                                                                          
  *MDD*                                  163(22.1)     126(17.7)     130(17.9)     117(18.1)     121(20.5)                      0.469(−0.72)
  Combined MDD                            24(3.3)       21(3.0)       23(3.2)       14(2.2)       24(4.1)                       0.764(0.30)
  Atypical MDD                            20(2.7)       22(3.1)       16(2.2)       18(2.8)       21(3.6)                       0.540(0.61)
  Melancholic MDD                         55(7.5)       43(6.0)       38(5.2)       34(5.3)       27(4.6)                       0.020(−2.32)
  Unspecified MDD                         64(8.7)       40(5.6)       53(7.3)       51(7.9)       49(8.3)                       0.700(0.38)
  *Any anxiety disorder*                 97(13.1)      71(10.0)      78(10.8)       50(7.7)       54(9.2)      0.005(−2.83)[\*](#nt105){ref-type="table-fn"}
  GAD                                     0(0.0)        0(0.0)        0(0.0)        0(0.0)        0(0.0)                             NA
  Panic disorder                          0(0.0)        1(0.1)        0(0.0)        0(0.0)        0(0.0)                             NA
  Agoraphobia                             16(2.2)       17(2.4)       23(3.2)       18(2.8)       10(1.7)                       0.869(−0.17)
  Social phobia                          85(11.5)       55(7.7)       59(8.1)       34(5.3)       45(7.6)      0.001(−3.21)[\*](#nt105){ref-type="table-fn"}

MDD =  major depressive disorder; GAD = generalized anxiety disorder; and SUA =  serum uric acid.

P-value \<0.05 for quadratic trend tested by a crude logistic model which included a quadratic term (SUA squared) for continuous value of SUA.

[**Table 3**](#pone-0076336-t003){ref-type="table"} shows the associations of SUA with MDD and anxiety disorders in the overall sample either from models with or without the quadratic term for SUA depending on whether quadratic or linear model was a better fit. Both crude and adjusted analyses showed significant inverse associations of SUA with lifetime and current social phobia. With regards to the other specific anxiety disorders and subtypes of MDD, we found no consistent pattern of association. Although we did not observe any significant interaction between sex and SUA for any of the lifetime and current psychiatric disorders, separate analysis in males and females are presented in **[Tables S3](#pone.0076336.s005){ref-type="supplementary-material"} and [S4](#pone.0076336.s006){ref-type="supplementary-material"}**.

10.1371/journal.pone.0076336.t003

###### Crude and adjusted logistic regression analysis of SUA (per 100 µmol/L) and psychiatric disorders in overall sample.
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                                                      Crude OR(95% CI)    Adjusted OR(95% CI)                                                                                             
  ------------------------------------------------- -------------------- --------------------- -------------------- ----------- -------------------- --------- ------------------ ------- ----------
  **Lifetime pyschiatric disorders**                                                                                                                                                      
  *MDD*                                              *0.66(0.60--0.72)*        *\<0.001*        *1.14(1.06--1.22)*   *\<0.001*   *0.94(0.84--1.05)*   *0.274*         *-*           *-*     0.308
  Combined MDD                                        0.71(0.59--0.86)          \<0.001                 \-              \-        1.01(0.80--1.27)     0.958           \-           \-      0.336
  Atypical MDD                                        0.81(0.68--0.97)           0.019                  \-              \-        1.11(0.88--1.38)     0.366           \-           \-      0.688
  Melancholic MDD                                     0.72(0.63--0.82)          \<0.001                 \-              \-        0.86(0.72--1.02)     0.089           \-           \-      0.260
  Unspecified MDD                                     0.85(0.77--0.95)           0.003                  \-              \-        0.96(0.84--1.10)     0.577           \-           \-      0.537
  *Any anxiety disorder*                             *0.70(0.63--0.78)*        *\<0.001*        *1.11(1.02--1.21)*    *0.019*    *0.89(0.77--1.03)*   *0.129*         *-*           *-*     0.983
  GAD                                                 0.93(0.71--1.22)           0.615                  \-              \-        1.06(0.75--1.51)     0.737           \-           \-      0.532
  Panic disorder                                      0.72(0.56--0.92)           0.008                  \-              \-        1.06(0.78--1.46)     0.700           \-           \-      0.735
  Agoraphobia                                         0.73(0.58--0.91)           0.005                  \-              \-        0.97(0.73--1.28)     0.811           \-           \-      0.722
  Social phobia                                       0.67(0.59--0.77)          \<0.001          1.15(1.04--1.27)      0.008      0.79(0.66--0.93)     0.005    1.12(1.01--1.24)   0.029   0.873^§^
  **Current psychiatric disorders**                                                                                                                                                       
  *MDD*                                              *0.78(0.70--0.87)*        *\<0.001*        *1.11(1.02--1.21)*    *0.012*    *1.04(0.90--1.19)*    0.610           \-           \-      0.841
  Combined MDD                                        0.79(0.62--1.01)           0.063                  \-              \-        1.16(0.86--1.58)     0.334           \-           \-      0.670
  Atypical MDD                                        0.90(0.70--1.15)           0.392                  \-              \-        1.19(0.87--1.64)     0.271           \-           \-      0.814
  Melancholic MDD                                     0.67(0.55--0.81)          \<0.001                 \-              \-        0.78(0.61--1.00)     0.054           \-           \-      0.556
  Unspecified MDD                                     0.97(0.83--1.13)           0.710                  \-              \-        1.11(0.91--1.37)     0.286           \-           \-      0.921
  *Any anxiety disorder*                             *0.66(0.57--0.75)*        *\<0.001*        *1.14(1.02--1.27)*    *0.024*    *0.83(0.69--0.99)*   *0.045*         *-*           *-*     0.075
  GAD[\*](#nt110){ref-type="table-fn"}                       NA                   NA                    NA              NA               NA             NA             NA           NA        NA
  Panic disorder[\*](#nt110){ref-type="table-fn"}            NA                   NA                    NA              NA               NA             NA             NA           NA        NA
  Agoraphobia                                         0.65(0.49--0.87)           0.004                  \-              \-        0.84(0.59--1.21)     0.352           \-           \-      0.948
  Social phobia                                       0.65(0.56--0.75)          \<0.001          1.22(1.09--1.37)      0.001      0.77(0.63--0.94)     0.009    1.19(1.06--1.34)   0.003   0.737^§^

MDD = major depressive disorder; GAD = generalized anxiety disorder; and SUA = serum uric acid.

If P value for the quadratic term (SUA^2^) is significant, ORs derived from models with quadratic term are presented.

Adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease equation) and drugs that influence uric acid and additionally for anxiety (in the association between SUA and depression) and depression (in the association between SUA and anxiety).

P~interaction~ = P value for multiplicative interaction parameter between SUA and sex; Interaction for models with a quadratic term was assessed using a likelihood ratio test (LRT) comparing a model which included SUA\*sex and SUA^2^\* sex and a model without; and §indicates P value of the LRT.

Logistic regression not possible due to zero prevalence; NA = not available.

The next set of analyses explored the association of uric acid with anxiety disorders using *SLC2A9 rs6588911* variant instead of phenotypic values for SUA. Logistic regression models ([**Table 4**](#pone-0076336-t004){ref-type="table"}) revealed significant interactions between sex and SUA as explained by the *SLC2A9 rs6855911* variant regarding any anxiety disorder (P-value for the interaction = 0.026 and 0.014 for lifetime and current disorders, respectively) and social phobia (P-value for the interaction = 0.033 and 0.015 for lifetime and current disorder, respectively). Therefore, we present all analyses regarding the association of the SUA-related *rs6855911* variant with anxiety disorders separately in men and women. While a significant positive association of the allele associated with higher SUA levels (*rs6855911* A allele) with lifetime and current social phobia was observed in men, a negative association, though not significant, was noticed in women. Considering that women have lower SUA levels than men at each *rs6855911* genotype (see below), the observed effect modification by sex is consistent with the quadratic association of SUA with social phobia in non-genetic analyses.

10.1371/journal.pone.0076336.t004

###### Crude and adjusted logistic regression analysis of *SLC2A9 rs6855911* and psychiatric disorders according to sex.
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                                                           Men          Women                             
  ------------------------------------ ------------ ------------------ ------- ------------------ ------- -------
  **Lifetime pyschiatric disorders**                                                                      
  *Any anxiety disorder*                Unadjusted   1.38(1.05--1.80)   0.019   0.94(0.78--1.14)   0.525  
                                         Adjusted    1.40(1.07--1.84)   0.015   0.97(0.80--1.17)   0.728   0.026
  GAD                                   Unadjusted   1.22(0.58--2.57)   0.601   0.94(0.58--1.51)   0.797  
                                         Adjusted    1.22(0.57--2.62)   0.602   0.94(0.58--1.52)   0.793   0.520
  Panic disorder                        Unadjusted   1.57(0.76--3.26)   0.225   0.80(0.55--1.15)   0.224  
                                         Adjusted    1.50(0.72--3.14)   0.277   0.82(0.56--1.19)   0.298   0.128
  Agoraphobia                           Unadjusted   1.50(0.77--2.92)   0.230   1.00(0.71--1.42)   0.979  
                                         Adjusted    1.61(0.82--3.18)   0.168   1.03(0.72--1.47)   0.865   0.287
  Social phobia                         Unadjusted   1.43(1.05--1.96)   0.025   0.93(0.75--1.17)   0.559  
                                         Adjusted    1.44(1.05--1.99)   0.023   0.96(0.76--1.21)   0.720   0.033
  **Current psychiatric disorders**                                                                       
  *Any anxiety disorder*                Unadjusted   1.42(1.00--2.03)   0.053   0.82(0.65--1.04)   0.097  
                                         Adjusted    1.42(0.99--2.03)   0.055   0.84(0.66--1.06)   0.140   0.014
  Agoraphobia                           Unadjusted   1.15(0.54--2.45)   0.713   0.84(0.54--1.29)   0.421  
                                         Adjusted    1.19(0.56--2.57)   0.649   0.85(0.55--1.32)   0.477   0.466
  Social phobia                         Unadjusted   1.51(1.02--2.25)   0.042   0.82(0.63--1.06)   0.124  
                                         Adjusted    1.50(1.00--2.23)   0.049   0.83(0.64--1.09)   0.184   0.015

GAD = generalized anxiety disorder.

ORs represent the effect of *SLC2A9 rs6855911* used as a continuous score of 0, 1 and 2 corresponding to GG, AG and AA genotype respectively with AA being the genotype associated with elevated levels of serum uric acid.

Adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease equation) and drugs that influence uric acid and additionally for anxiety (in the association between SUA and depression) and depression (in the association between SUA and anxiety).

P~interaction~ = P value for sex-by-genotype interaction for its effect on psychiatric disorders.

We present the distribution of SUA and anxiety disorders across SUA-related *rs6855911* variant separately in men and women in [**Table 5**](#pone-0076336-t005){ref-type="table"}. In women, a negative (although not significant) linear trend of social phobia was noted across genotypes associated with increasing levels of SUA similar to that observed in [Table S2](#pone.0076336.s004){ref-type="supplementary-material"} using phenotypic SUA levels. On the other hand, a significant positive linear trend was seen in men, which was in contrast to that observed in women and also to the analysis that used SUA phenotype (in [Table S1](#pone.0076336.s003){ref-type="supplementary-material"}). Further, we graphically displayed in **[Figure S2](#pone.0076336.s002){ref-type="supplementary-material"}** the distribution of SUA and prevalence of social phobia across genotypes of the variant *SLC2A9 rs6855911* separately in men and women. Both men and women who carried the AA genotype had elevated levels of SUA as compared to carriers of the GG genotype. While in women a lower prevalence of social phobia was found in carriers of the AA genotype associated with higher SUA levels, the opposite trend was observed in men. Further, we observed a P-value of 0.014 for a LRT for a quadratic trend using the genetic variable coded as 0, 1, 2, 3, 4 and 5 where 0 = GG in females, 1 = AG in females, 2 = AA in females, 3 = GG in males, 4 = AG in males and 5 = AA in males (data not shown). This coding was chosen because it ranks these 6 independent groups of people according to increasing lifelong SUA levels. Taken together, these results are consistent with a quadratic relationship between *SLC2A9* genotypes (i.e. genetically determined SUA levels) and social phobia, which was similar to what we observed in [Figure S1](#pone.0076336.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0076336.t005

###### Distribution of SUA and psychiatric outcomes across genotypes of *SLC2A9 rs6855911* in men and women.
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                                                    GG              AG              AA         P-trend
  ------------------------------------------- --------------- --------------- --------------- ---------
  **MEN (N)**                                       107             544             706       
  **SUA (mean, SD) µmol/L**                    317.96(76.11)   352.57(69.60)   367.63(74.75)   \<0.001
  **Lifetime pyschiatric disorders (N, %)**                                                   
  *Any anxiety disorders*                         8(7.55)        62(11.44)      104(14.81)      0.014
  GAD                                             1(0.94)         7(1.29)        11(1.57)       0.556
  Panic disorder                                  0(0.00)         9(1.66)        14(1.99)       0.203
  Agoraphobia                                     2(1.89)         7(1.29)        18(2.57)       0.211
  Social phobia                                   6(5.66)        42(7.75)        77(10.98)      0.019
  **Current psychiatric disorders (N, %)**                                                    
  *Any anxiety disorders*                         5(4.67)        31(5.70)        59(8.36)       0.044
  Agoraphobia                                     2(1.87)         5(0.92)        11(1.56)       0.694
  Social phobia                                   3(2.80)        26(4.78)        49(6.94)       0.034
  **WOMEN (N)**                                     108             653             780       
  **SUA (mean, SD) µmol/L**                    220.73(50.36)   251.60(61.36)   278.87(62.69)   \<0.001
  **Lifetime pyschiatric disorders (N, %)**                                                   
  *Any anxiety disorders*                        23(21.50)      161(24.73)      170(21.88)      0.463
  GAD                                             3(2.80)        20(3.07)        21(2.70)       0.767
  Panic disorder                                  5(4.67)        37(5.68)        30(3.87)       0.215
  Agoraphobia                                     6(5.61)        37(5.68)        44(5.66)       0.996
  Social phobia                                  18(16.82)       99(15.21)      112(14.41)      0.492
  **Current psychiatric disorders (N, %)**                                                    
  *Any anxiety disorders*                        19(17.59)       89(13.63)       92(11.79)      0.083
  Agoraphobia                                     5(4.63)        23(3.52)        24(3.08)       0.404
  Social phobia                                  16(14.81)       69(10.57)       73(9.36)       0.108

GAD = generalized anxiety disorder; and SUA = serum uric acid.

The results are expressed as numbers and percentages except for SUA which is expressed as mean and standard deviation.

Sex-by-genotype interaction were significant for its effect on lifetime and current any anxiety disorders and social phobia ([Table 4](#pone-0076336-t004){ref-type="table"}).

Discussion {#s4}
==========

To the best of our knowledge, this is by far the largest population-based study to assess the relationship of SUA with depressive and anxiety disorders. We found a significant quadratic (hockey-stick shaped) association between SUA with both lifetime and current social phobia suggesting that elevated levels of SUA are associated with lower frequency of social phobia only up to a certain concentration after which increasing SUA levels are no longer protective. It is interesting to note that SUA does not appear to be protective when in the range of hyperuricemia.

We observed a similar quadratic relationship between *SLC2A9 rs6855911* (associated with increasing levels of uric acid) and social phobia when keeping both men and women in the analysis. Similar to what was observed for the non-genetic association, the overall quadratic association of *rs6855911* genotypes with social phobia disappeared when stratifying the analyses by sex. Findings from genetic associations are generally considered to be free from the inherent problems of reverse causation and confounding. Recent genome wide association studies have identified *SLC2A9* gene, a putative hexose transporter, to be strongly associated with SUA [@pone.0076336-Vitart1], [@pone.0076336-Doring1], [@pone.0076336-Li1]. *SLC2A9* gene explains a substantial proportion (1--6%) of the variance in SUA concentration [@pone.0076336-Le1]. Considering that genes are inherited at the time of conception from parents through random transmission, genetic associations of single nucleotide polymorphisms (SNPs) within or around the genes will be less likely to be influenced by problems of reverse causality or measurement errors inherent to conventional observational studies and more likely to produce robust causal inferences. The results of the genetic associations for social phobia using the *SLC2A9 rs6855911* variant serve to validate the findings of the observational analysis. It confirmed the finding that SUA does not confer protective effects beyond a certain concentration as evidenced from the negative association (i.e., those carrying the allele related to elevated levels of SUA were associated with decreased risk of social phobia) observed in women and the opposite association in men. Women have much lower SUA levels than men [@pone.0076336-Culleton1], due to the uricosuric effects of estrogen [@pone.0076336-Nicholls1]. Our findings provide new insights which need to be replicated in other settings.

Very few studies have explored the association between SUA and anxiety disorders. The earliest study dating back to 1979 and carried out on 20 students aged between 18--30 years found levels of SUA to be significantly decreased during periods of anxiety [@pone.0076336-Francis1]. Similar decreases in SUA levels in stressful situations have been observed. Trevisan et al. observed exposure to a natural disaster (major earthquake) in 578 healthy factory workers in Naples to be associated in the short term with a reduction and in the long-term with an increase in SUA levels [@pone.0076336-Trevisan1]. More recently, a study in Japan found no association between SUA and post-traumatic stress disorder in 34 victims of the Tokyo Sarin attack. However, the authors do acknowledge that lack of association could have been due to the limited sample size and 5-year time gap between the event and the study [@pone.0076336-Tochigi1]. Our finding of an inverse association between SUA level and social phobia (the most common anxiety disorders [@pone.0076336-Kessler2]), which is an indicator of permanent social stress, are consistent with previous studies that reported decreased SUA levels in periods of stress and anxiety. Similar findings were also documented from longitudinal studies on US navy men undergoing training as a part of the Navy Underwater Demolition Team [@pone.0076336-Rahe1], [@pone.0076336-Rahe2], [@pone.0076336-Zir1]. SUA varied significantly with elevated levels during periods of rigorous training for challenging tasks that were eagerly awaited and decreased levels during periods of unanticipated intense psychological and physical stress. Moreover, a similar experiment by the same group on three medical investigators over six-month periods also revealed increases in SUA levels above baseline in situations prior to a physical challenge in which the associated stress is eagerly anticipated as a pleasant challenge [@pone.0076336-Rahe3].

Although three previous studies documented negative associations between SUA level and depression, we did not find such an association of SUA with MDD or its subtypes. In the first study of 826 individuals with age ranging from 16--86 years Wen et al found depressive patients (based on scores from the Hamilton Depression Scale (HAMD24)) to have significantly lower SUA levels as compared to patients with other mental disorders and healthy controls [@pone.0076336-Wen1]. Similarly, a significant negative correlation between SUA and Zung Self-Rating Depression Scale scores was observed in another population-based (the Massa Lombarda Project) study on 106 subjects with a mean age of about 80 years [@pone.0076336-Bove1]. The third study, a randomized controlled trial, among age and sex-matched 40 MDD based on the Hamilton Rating Scale for Depression scores and 36 healthy subjects before and after anti-depressive drug treatment found significantly lower SUA levels in newly diagnosed MDD subjects compared to healthy subjects with a reverse trend after 12 weeks of treatment [@pone.0076336-Chaudhari1]. Differences in the sampling or the use of different instruments to assess depression are likely to account for the different results in the present study as compared to the three previous studies. Indeed, two of the three previous studies included treated depressive subjects, who were likely to be more severely affected than the depressive sample of the present population-based study.

The exact mechanisms of action linking SUA with anxiety disorders still remains elusive. Oxidative stress has recently gained attention as one of the suggested mechanisms in the pathophysiology of MDD and anxiety disorders. Evidence from experimental studies clearly supports this hypothesis [@pone.0076336-Bouayed1], [@pone.0076336-Hovatta1], [@pone.0076336-Hovatta2], [@pone.0076336-Salim1]. These findings further extend to studies in humans where elevated oxidative stress levels have been observed in patients with depression [@pone.0076336-Yanik1], [@pone.0076336-Cumurcu1], [@pone.0076336-Irie1], [@pone.0076336-Sarandol1] and anxiety [@pone.0076336-Matsushita1]. Oxidative stress characterized by an excess generation of reactive oxygen species can affect a number of physiological functions including the central nervous system. The brain has modest antioxidant levels and is particularly vulnerable to the detrimental effects of oxidative stress as the neuronal membrane containing a high proportion of polyunsaturated fatty acids is a key site for oxidative stress [@pone.0076336-Fendri1]. Uric acid, by virtue of its powerful anti-oxidant properties [@pone.0076336-Ames1], may provide a defense against the oxidative stress [@pone.0076336-Klandorf1]. In addition, recent observations have also attributed the protective effect of SUA to its ability to decrease blood-brain barrier permeability as well as a more direct effect on astroglial cells [@pone.0076336-Du1], [@pone.0076336-Spitsin1]. However, the relation between SUA and anxiety may not be as straightforward as it appears, which is also reflected in the non-linear relationship observed in the current study. This is not surprising and probably relates to the complex and paradoxical role of uric acid in the "antioxidant -- prooxidant urate redox shuttle" which states that "in a prooxidative environmental milieu the original antioxidant properties of uric acid paradoxically become prooxidant" [@pone.0076336-Hayden1]. Furthermore, it is difficult to distinguish whether lowered SUA levels observed in depressed and anxious subjects is a cause or consequence of the disease. As Wen and colleagues pointed out, it is unclear if depressed patients with low SUA levels are more likely to be challenged with free radical toxicity and inflammation or rather low SUA is due to the consumption of uric acid by radical interaction and damaged tissue encountered in anxiety or depression [@pone.0076336-Wen1].

The strengths of this study are its population-based design, the large sample size, the face-to-face structured interview-based psychiatric diagnoses, the availability of detailed information on a number of potential confounders known to influence the association and the accessibility to genetic markers that allowed for validating the findings from phenotypic analyses. The potential limitations are: first, the cross-sectional nature of the study with the establishment of lifetime diagnoses of MDD and anxiety disorders which did not allow us to infer causality of non-genetic findings. However, the findings from the genetic analysis using *SLC2A9 rs6855911* corroborated the results from the phenotypic analysis (where SUA was used). Indeed, inferences drawn from genetic analyses are usually more robust and can be considered as causal. Second, there was a gap of about one year \[median (interquartile range) being 1.2(1.1--1.3) years\] between the evaluation of SUA and assessments of psychiatric phenotypes. However, evidence have shown that SUA taken 5 years apart have a high correlation (r = 0.50) [@pone.0076336-Spyckerelle1] which makes it unlikely that the subjects would have very different levels of SUA after an interval of one year.

In conclusion, in this population-based sample, we found a quadratic (hockey-stick shaped) relation between SUA and social phobia, with both non-genetic and genetic associations, consistent with a potential protective effect of moderately elevated SUA on social phobia, which disappears when SUA levels reach the hyperuricemic zone. Since the use of genetic variants reflecting lifelong differences in SUA levels is usually robust to confounding and reverse causality, our results suggest that the observed association may be causal. However, prospective observational and experimental studies are needed to confirm our observations.
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**A quadratic curve association between serum uric acid (SUA) and social phobia.** The dots and bars represent the adjusted probabilities along with 95%CI of social phobia across SUA levels. Solid line represents the fitted quadratic curve of the effect of SUA on social phobia. Adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease equation), drugs that influence uric acid and depression.

(TIF)
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Click here for additional data file.

###### 

**Distribution of serum uric acid (SUA) and current social phobia across genotypes of** ***SLC2A9 rs6855911*** **in men and women.** ♀ = women; ♂ = men. Red and blue barplots indicate mean SUA across the genotypes of SLC2A9 rs6855911 in women and men respectively. Black diamonds with bars indicate adjusted prevalence and 95% CI of social phobia across the genotypes GG, AG and AA of the SLC2A9 rs6855911 variant. Prevalence adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease equation), drugs that influence uric acid and depression.

(TIF)
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Click here for additional data file.

###### 

**Distribution of psychiatric disorders across sex-specific quintiles of SUA in males.** MDD = major depressive disorder; GAD = generalized anxiety disorder; and SUA = serum uric acid. \*P-value\<0.05 for quadratic trend tested by a crude logistic model which included a quadratic term (SUA squared) for continuous value of SUA.
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**Distribution of psychiatric disorders across sex-specific quintiles of SUA in females.** MDD = major depressive disorder; GAD = generalized anxiety disorder; and SUA = serum uric acid. \*P-value\<0.05 for quadratic trend tested by a crude logistic model which included a quadratic term (SUA squared) for continuous value of SUA.
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Click here for additional data file.

###### 

**Crude and adjusted logistic regression analysis of SUA (per 100 µmol/L) and psychiatric disorders in males.** MDD = major depressive disorder; GAD = generalized anxiety disorder; and SUA = serum uric acid.If P value for the quadratic term (SUA2) is significant, ORs derived from models with quadratic term are presented.Adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease equation) and drugs that influence uric acid and additionally for anxiety (in the association between SUA and depression) and depression (in the association between SUA and anxiety). \*Logistic regression not possible due to zero prevalence; NA = not available.
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Click here for additional data file.

###### 

**Crude and adjusted logistic regression analysis of SUA (per 100 µmol/L) and psychiatric disorders in females.** MDD = major depressive disorder; GAD = generalized anxiety disorder; and SUA = serum uric acid. If P value for the quadratic term (SUA2) is significant, ORs derived from models with quadratic term are presented. Adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease equation) and drugs that influence uric acid and additionally for anxiety (in the association between SUA and depression) and depression (in the association between SUA and anxiety). \*Logistic regression not possible due to zero prevalence; NA = not available.
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Click here for additional data file.
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